Isotechnika Receives European Patent for Lead Immunosuppressive Drug, ISA247

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announcedtoday that the Company has been issued European Patent No. EP0991660for its lead immunosuppressive drug, ISA247. The patent entitled"DEUTERATED AND UNDEUTERATED CYCLOSPORINE ANALOGS AND THEIR USE ASIMMUNOMODULATING AGENTS" is the ninth patent to be issuedinternationally in this patent family. Patents relating to theseclaims have issued in the following countries; Australia (No.750245, issued July 11, 2002 and No. 774744 issued October 21,2004), Canada (No. 2,298,572 issued April 9, 2002 and No. 2,372,639issued November 1, 2005); New Zealand (No. 502362 issued September6, 2001), South Korea (No. 585348, issued June 1, 2006) and theUnited States (No. 6,605,593 issued August 12, 2003 and No.6,613,739 issued September 2, 2003).

"We are pleased to add another international patent in a majormarket to our portfolio," stated Dr. Randall Yatscoff, Isotechnika'sPresident and Chief Executive Officer. "Several additionalpatentable claims for ISA247 continue to be investigated and pursuedwhere appropriate."

About Isotechnika


Isotechnika Inc. is an international biopharmaceutical companyheadquartered in Edmonton, Alberta, Canada. Drawing upon itsexpertise in medicinal chemistry and immunology, the Company isfocused on the discovery and development of novel immunosuppressivetherapeutics that are safer than currently available treatments. Itsentrepreneurial management and world- class team of scientists arebuilding a pipeline of immunosuppressive drug candidates fortreatment of autoimmune diseases and for use in the prevention oforgan rejection in transplantation. Isotechnika looks to become theleader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 has completed an extensionprotocol of a Canadian Phase III human clinical trial for thetreatment of moderate to severe psoriasis and is currently involvedin a North American Phase IIb human clinical trial for theprevention of kidney graft rejection . The Company also has anadditional immunosuppressive compound in its drug pipeline, TAFA93which successfully completed Phase I clinical trials.

Isotechnika Inc. is a publicly traded company on the Toronto StockExchange under the symbol ISA. More information on Isotechnika can befound at www.isotechnika.com.

Partnerships with Isotechnika Inc.


Isotechnika Inc. signed a collaboration agreement with Hoffman LaRoche on April 9, 2002, which licensed the worldwide rights todevelop and commercialize ISA247 for all transplant indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusiveworldwide licensing agreement with Atrium Medical Corporation for theuse of ISA247 and TAFA93 specifically with drug eluting devices forthe non- systemic treatment of vascular, cardiovascular, targetvessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement onApril 25, 2006, granting Isotechnika the option to obtain anexclusive license to develop and commercialize conjugates consistingof Cellgate's patented transporter technology for the topicaldelivery of ISA247 in patients suffering from mild to moderatepsoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with LuxBiosciences, Inc. of Jersey City, New Jersey granting Lux Biosciencesworldwide rights to develop and commercialize Isotechnika's leaddrug, ISA247 for the treatment and prophylaxis of all ophthalmicdiseases.

Forward-Looking Statements


This press release may contain forward-looking statements. Forwardlooking statements, including the Company's belief as to thepotential of its products, the Company's expectations regarding theissuance of additional patents and the Company's ability to protectits intellectual property, involve known and unknown risks anduncertainties, which could cause the Company's actual results todiffer materially from those in the forward looking statements. Suchrisks and uncertainties include, among others, the availability offunds and resources to pursue research and development projects, theability to economically manufacture its products, the potential ofits products, the success and timely completion of clinical studiesand trials, the Company's ability to successfully commercialize itsproducts, the ability of the Company to defend its patents frominfringement by third parties, and the risk that the Company'spatents may be subsequently shown to be invalid or infringe thepatents of others. Investors should consult the Company's quarterlyand annual filings with the Canadian commissions for additionalinformation on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing unduereliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.Im Internet recherchierbar: http://www.presseportal.de

Contact:For further information: Dr. Randall Yatscoff, President & CEO, Isotechnika Inc., +1-(780)-487-1600 (246), +1-(780)-484-4105 (fax), ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Corporate Communications, Isotechnika Inc., +1-(780)-487-1600 (243), +1-(780)-487-1500 (fax), sgillis-paulgaard@isotechnika.com

Isotechnika Inc.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Isotechnika Receives European Patent for Lead Immunosuppressive Drug, ISA247